Close Menu

NEW YORK – CareDx reported after the close of the market on Tuesday that its second quarter revenues rose 33 percent year over year, thanks largely to a 41 percent increase in testing services revenues.

For the three months ended June 30, the molecular diagnostics company reported total revenues of $41.8 million, up from $31.5 million during the same period a year earlier, beating the average Wall Street estimate of $35.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.